$AIRS

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November - AirSculpt Technologies (NASDAQ:AIRS), Inotiv (NASDAQ:NOTV)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.

Original reporting
Benzinga · Avi Kapoor
Published Nov 18, 2025, 11:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 18, 2025, 12:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November - AirSculpt Technologies (NASDAQ:AIRS), Inotiv (NASDAQ:NOTV) — source image
Decision brief

The 30-second read

$AIRSNeutralMed
01

Why it matters

The focus on undervalued stocks indicates a potential short-term rebound, but investors should consider broader sector health and company fundamentals.

02

Market read

The health care sector is experiencing oversold conditions, presenting potential short-term trading opportunities for sector-focused traders.

03

What to watch

Potential upcoming earnings reports or sector regulatory changes could negatively impact these stocks, offsetting short-term gains.

Timing: Short-term (next 2-4 weeks)

Background

The article highlights oversold stocks in the health care sector, suggesting buying opportunities based on technical indicators like RSI.

Company-level read

Ticker impact

$AIRSNeutralMedium confidence
Context

High relevance due to positive sentiment and sector importance.

Expected impact

Moderate upward movement expected over the next 2-4 weeks.

Evidence & confidence

The stock is identified as oversold with a neutral sentiment, indicating potential for a rebound, but technical and fundamental data are limited.

$NOTVNeutralMedium confidence
Context

Moderate relevance; sentiment is neutral, and company is part of the health care sector.

Expected impact

Possible slight upward correction in the short term.

Evidence & confidence

The neutral sentiment and oversold condition suggest some recovery potential, but lack of strong catalysts limits confidence.

Market effects

Positive sentiment towards undervalued health care stocks may boost sector confidence.

Potentially favorable in North American markets where these stocks are listed.

Limited; focus is primarily on U.S. health care sector stocks.

Counterpoint

The stocks may remain undervalued longer than expected due to sector headwinds or company-specific issues.

Key entities

  • AirSculpt Technologies

    A provider of minimally invasive body contouring procedures.

  • Inotiv

    A contract research organization serving the life sciences industry.

  • Stimulant Therapeutics

    A biotech firm focusing on novel therapeutic agents.

Related articles

$AIRSMedAI 8/10

AirSculpt (AIRS) Q2 2026 Earnings Call Transcript

AirSculpt Technologies (AIRS) reported Q2 2026 revenue of $42.9M, down 3% from $44.0M a year earlier. Q2 case volume was 3,376, slightly down, while gross margin rose to 61.2%. Adjusted EBITDA was $4.9M. Full-year revenue guidance is $151M to $157M and Adjusted EBITDA $12M to $14M, revised lower on added marketing. Cash was $18.8M; debt was $44.2M.

$TENXHighAI 8/10

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

U.S. stock index futures edged higher as investors weighed fading Middle East deal hopes and upcoming inflation data. Tenax Therapeutics shares fell 84.2% after Phase 3 TNX-103 missed endpoints. Sionna Therapeutics dropped 92.1% after Phase 2a SION-719 failed. MarineMax rose over 34% on a reported $1.5B Safe Harbor Marinas buyout. AAON, Silence, Dole, and AirSculpt also moved premarket on updates.

$AIRSHighAI 9/10

Why is AirSculpt Technologies stock tumbling today?

Investing.com reports AirSculpt Technologies (AIRS) shares fell about 18.4% in pre-open after its Q2 fiscal 2026 earnings. Revenue was $42.9M, down 3% YoY, with net loss of $1.1M and Adjusted EBITDA $4.9M (11.5% margin). Guidance was revised to the lower end of $151–$157M revenue and Adjusted EBITDA $12–$14M.

$AIRSMed

Airsculpt Technologies, Inc. (AIRS): Results of Operations and Financial Condition

Airsculpt Technologies, Inc. (AIRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results Same Center Cases Up 1% for the Second Consecutive Quarter MIAMI BEACH, Fla., August 10, 2026 (GLOBE NEWSWIRE) – AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national pro

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.